Immune Design Corp (IMDZ) Expected to Post Quarterly Sales of $810,000.00

Equities analysts forecast that Immune Design Corp (NASDAQ:IMDZ) will post $810,000.00 in sales for the current fiscal quarter, Zacks Investment Research reports. Two analysts have provided estimates for Immune Design’s earnings, with estimates ranging from $400,000.00 to $1.22 million. Immune Design posted sales of $2.06 million during the same quarter last year, which would indicate a negative year over year growth rate of 60.7%. The company is expected to report its next quarterly earnings report on Tuesday, March 6th.

According to Zacks, analysts expect that Immune Design will report full year sales of $810,000.00 for the current year, with estimates ranging from $7.10 million to $9.00 million. For the next fiscal year, analysts anticipate that the business will post sales of $16.37 million per share, with estimates ranging from $14.73 million to $18.00 million. Zacks’ sales calculations are an average based on a survey of research analysts that that provide coverage for Immune Design.

Immune Design (NASDAQ:IMDZ) last posted its quarterly earnings results on Wednesday, November 1st. The biotechnology company reported ($0.52) EPS for the quarter, beating the consensus estimate of ($0.63) by $0.11. The firm had revenue of $0.52 million during the quarter, compared to analysts’ expectations of $0.62 million. Immune Design had a negative return on equity of 68.69% and a negative net margin of 619.62%.

IMDZ has been the subject of several recent research reports. Cowen reaffirmed a “buy” rating on shares of Immune Design in a report on Monday, December 11th. Wells Fargo & Co cut Immune Design from an “outperform” rating to a “market perform” rating and cut their price target for the company from $29.00 to $10.00 in a report on Tuesday, October 17th. ValuEngine cut Immune Design from a “sell” rating to a “strong sell” rating in a report on Saturday, October 21st. Zacks Investment Research cut Immune Design from a “buy” rating to a “hold” rating in a report on Friday, November 10th. Finally, Royal Bank of Canada initiated coverage on Immune Design in a report on Thursday, September 14th. They issued an “outperform” rating and a $20.00 price target for the company. One analyst has rated the stock with a sell rating, one has given a hold rating and five have issued a buy rating to the company. The company currently has an average rating of “Buy” and an average target price of $13.06.

Immune Design (IMDZ) opened at $4.05 on Friday. The company has a market capitalization of $194.64, a P/E ratio of -1.90 and a beta of 2.36. Immune Design has a twelve month low of $3.50 and a twelve month high of $13.05.

In related news, Director Peter Svennilson acquired 2,681,000 shares of the stock in a transaction dated Friday, October 27th. The shares were bought at an average cost of $4.10 per share, for a total transaction of $10,992,100.00. The acquisition was disclosed in a filing with the SEC, which is available at the SEC website. Also, major shareholder Leo Guthart purchased 10,000 shares of the firm’s stock in a transaction that occurred on Thursday, October 19th. The shares were acquired at an average price of $6.09 per share, for a total transaction of $60,900.00. The disclosure for this purchase can be found here. Over the last quarter, insiders bought 5,290,000 shares of company stock worth $21,777,900. Corporate insiders own 20.70% of the company’s stock.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. State of Wisconsin Investment Board bought a new stake in Immune Design during the 2nd quarter worth approximately $117,000. Alliancebernstein L.P. bought a new stake in Immune Design during the 2nd quarter worth approximately $118,000. Bank of America Corp DE grew its position in Immune Design by 123.3% during the 1st quarter. Bank of America Corp DE now owns 15,246 shares of the biotechnology company’s stock worth $104,000 after acquiring an additional 8,418 shares during the last quarter. Virtu KCG Holdings LLC bought a new stake in Immune Design during the 2nd quarter worth approximately $153,000. Finally, Dimensional Fund Advisors LP grew its position in Immune Design by 9.3% during the 2nd quarter. Dimensional Fund Advisors LP now owns 18,896 shares of the biotechnology company’s stock worth $184,000 after acquiring an additional 1,600 shares during the last quarter. Institutional investors and hedge funds own 29.34% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This piece of content was first reported by American Banking News and is owned by of American Banking News. If you are reading this piece of content on another domain, it was illegally copied and reposted in violation of United States & international copyright legislation. The correct version of this piece of content can be read at https://www.americanbankingnews.com/2018/01/05/immune-design-corp-imdz-expected-to-post-quarterly-sales-of-810000-00.html.

About Immune Design

Immune Design Corp. is a clinical-stage immunotherapy company. The Company is focused on cancer with in vivo approaches designed to enable the body’s immune system to fight disease. The Company has engineered its technologies to activate the immune system’s natural ability to create tumor-specific cytotoxic T cells (CTLs) to fight cancer.

Get a free copy of the Zacks research report on Immune Design (IMDZ)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Immune Design (NASDAQ:IMDZ)

Receive News & Ratings for Immune Design Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immune Design and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply